MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC
Benjamin Besse(Institut Gustave Roussy), E. Felip(Universitat Autònoma de Barcelona), L. Paz-Ares(Hospital Universitario 12 De Octubre), M. D’Arcangelo(Harbin Medical University), B.C. Cho(Yonsei University), Sebastian Michels(University Hospital Cologne), Isabelle Leconte(Actelion (Switzerland)), D.-W. Kim(Seoul National University Hospital), Zhuang Jiang(Johnson & Johnson (United States)), Christina S. Baik(Seattle Cancer Care Alliance), J.C. Curtin(Janssen (United States)), Mahadi Baig(Johnson & Johnson (United States)), R.E. Sanborn(Providence Portland Medical Center), S.-H. Lee(Samsung Medical Center), Zacharias Anastasiou(Johnson & Johnson (United States)), Jie Yang(National Taiwan University), Y. Wang(Sichuan University), Shun Lu(Shanghai Jiao Tong University), Xiaohui Luo(Fujian Medical University), Chun‐Ting Lin(Chung Shan Medical University Hospital), Leonardo Trani(Springhouse), Marcia Cruz–Correa(University of Puerto Rico, Medical Sciences Campus), P. Tomasini(Inserm)
Cited by 1
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
|The Lancet Oncology|2022|738
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2011|713